<DOC>
	<DOCNO>NCT00975806</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose , safety , effectiveness lenalidomide ( CC-5013 ) administer combination sunitinib treatment patient renal cell carcinoma .</brief_summary>
	<brief_title>Study Lenalidomide Combination With Sunitinib Evaluate Safety Efficacy Patients With Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Metastatic Renal Cell Carcinoma . 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 1 . 1 . Prior chemotherapy . 2 . Prior treatment lenalidomide , thalidomide , pomalidomide , sunitinib . 3 . Laboratory value outside normal range . 4 . Myocardial infarction ( MI ) within past 12 month . 5 . Current congestive heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>